What Is the 340B Rebate Model Pilot, and Why Is It Back Now?

The 340B rebate model pilot is HRSA’s proposed replacement for upfront 340B discounts. Under this model, for a defined set of drugs, instead of getting the purchase price, covered entities would dispense at full price and then submit a rebate request to the manufacturer after the fact. HRSA’s latest move restarts this effort with a proposed January 1, 2027 start date, after the original version was blocked in court before it ever took effect.

This isn’t a new idea. It’s the second attempt at a fight that already went through a full legal cycle in the past year.

What Happened to the First Version of This Pilot?

HRSA’s original rebate model pilot was set to begin January 1, 2026, covering roughly 11 manufacturers and 25 products tied to CMS’s Medicare Drug Price Negotiation Program for 2026. Hospital groups sued, and the U.S. District Court for the District of Maine issued a preliminary injunction blocking it before launch. In February 2026, the court vacated and remanded the pilot’s application notice and manufacturer approvals back to HHS. HHS then formally withdrew the pilot and agreed to new guardrails for any future attempt.

That’s the version most covered entities had already mentally filed away as dead. It isn’t.

What’s Different About the Reproposed 2027 Pilot?

Two things changed, and both make this version bigger than the one that got struck down:

  1. Wider drug scope. The original pilot covered only drugs subject to Medicare price negotiation for 2026. The reproposed version extends to manufacturers participating in the Medicare Drug Price Negotiation Program for both initial price applicability years (IPAY) 2026 and 2027, nearly double the negotiated-drug list. Forvis Mazars estimates this puts roughly 30% of all 340B rebates in scope once finalized.
  2. A later, more deliberate timeline. HRSA submitted a pre-rule notice to the White House Office of Management and Budget on May 27, 2026, and has been issuing information collection requests (ICRs) to work through the Administrative Procedure Act problems that got the first version blocked rather than rushing straight to another application notice.

The mechanics stay the same as before: this remains voluntary for manufacturers, and covered entities would need new systems to capture dispensing data and submit rebate requests within timely filing windows a fundamentally different operational model than the discount-at-purchase process most programs run today.

What Hasn’t HRSA Decided Yet?

HRSA has explicitly said that data submission standards, frequency, and technical specifications will come in a future Federal Register notice — they aren’t settled yet. Also still open: how fast rebates actually get processed, what dispute resolution looks like when a rebate is denied or delayed, and how this coordinates with Medicaid and Medicare billing. Covered entities are being asked to prepare for a model whose exact mechanics aren’t fully published.

What Should Covered Entities Do Right Now?

Nothing changes operationally today this is a proposal working through the same rulemaking process the first version failed to complete, and it can still be challenged again. But three things are worth doing now rather than waiting for the final rule:

  1. Map financial exposure. If ~30% of your 340B rebates could shift to a rebate-after-dispense model, know which drugs and which revenue that touches before it’s mandatory.
  2. Audit data capture today. A rebate model needs clean, timely, claim-level dispensing data tied to the negotiated drug list most legacy TPA setups weren’t built to produce that on a rebate-cycle timeline.
  3. Don’t treat “voluntary for manufacturers” as “optional to prepare for.” If even a handful of the largest manufacturers opt in, the covered entities buying their drugs don’t get a choice.

FAQ

Is the 340B rebate model pilot mandatory? It’s voluntary for manufacturers to opt in. Covered entities that buy drugs from a participating manufacturer would need to follow the rebate process for those specific drugs; they don’t get to opt out individually.

When does the new pilot start? HRSA has proposed a January 1, 2027 start date. This is not finalized; the proposal is still moving through federal rulemaking, and the first version of this pilot was blocked in court after a similar stage in the process.

Which drugs are covered? Manufacturers participating in CMS’s Medicare Drug Price Negotiation Program for initial price applicability years 2026 and 2027 an expansion from the original pilot’s 2026-only scope.

What happened to the original January 2026 pilot? It was blocked by a federal court before launch, then vacated and remanded to HHS in February 2026. HHS formally withdrew it and agreed to new guardrails before attempting again.

Has HRSA published the technical requirements yet? No. Data submission standards, frequency, and technical specifications are still pending a future Federal Register notice.

Sources: